MiNK Therapeutics (INKT) Institutional Ownership $0.70 +0.02 (+2.92%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for MiNK Therapeutics (NASDAQ:INKT)CurrentInstitutional OwnershipPercentage2.87%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$21.46KNumber ofInstitutional Sellers(last 12 months)0 Get INKT Insider Trade Alerts Want to know when executives and insiders are buying or selling MiNK Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data INKT Institutional Buying and Selling by Quarter Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] MiNK Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/9/2024 Renaissance Technologies LLC127,841$121K0.0%+21.5%0.368% 11/14/2023 Oracle Investment Management Inc.36,898$41K0.0%-26.9%0.107% 8/14/2023 Oracle Investment Management Inc.50,461$106K0.1%N/A0.146% 8/14/2023 Deep Track Capital LP324,867$682K0.0%N/A0.941% 8/11/2023 Artal Group S.A.228,216$479K0.0%-21.2%0.663% 7/27/2023Virtu Financial LLC14,232$30K0.0%N/A0.041% 2/10/2023 StoneX Group Inc.17,821$47K0.0%N/A0.053% 11/4/2022First Republic Investment Management Inc.81,500$172K0.0%N/A0.243% 2/15/2022 Sofinnova Investments Inc.345,499$1.54M0.1%N/A1.031% (Data available from 1/1/2016 forward) INKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INKT shares? During the previous two years, the following institutional investors and hedge funds held shares of MiNK Therapeutics shares: Deep Track Capital LP ($682K), Artal Group S.A. ($479K), Renaissance Technologies LLC ($121K), StoneX Group Inc. ($47K), and Oracle Investment Management Inc. ($41K), Virtu Financial LLC ($30K).Learn more on INKT's institutional investors. What percentage of MiNK Therapeutics stock is owned by institutional investors? 2.87% of MiNK Therapeutics stock is owned by institutional investors. Learn more on INKT's institutional investor holdings. Which institutional investors have been buying MiNK Therapeutics stock? The following institutional investors have purchased MiNK Therapeutics stock in the last 24 months: Deep Track Capital LP ($324.87K), Oracle Investment Management Inc. ($50.46K), Renaissance Technologies LLC ($22.61K), StoneX Group Inc. ($17.82K), and Virtu Financial LLC ($14.23K). How much institutional buying is happening at MiNK Therapeutics? Institutional investors have bought a total of 429,994 shares in the last 24 months. This purchase volume represents approximately $886.05K in transactions. Which MiNK Therapeutics major shareholders have been selling company stock? The following institutional investors have sold MiNK Therapeutics stock in the last 24 months: Artal Group S.A. ($61.37K), and Oracle Investment Management Inc. ($13.56K). How much institutional selling is happening at MiNK Therapeutics? Institutional investors have sold a total of 74,935 shares in the last 24 months. This volume of shares sold represents approximately $143.80K in transactions. Related Companies Elevation Oncology Institutional Ownership Precision BioSciences Institutional Ownership Atara Biotherapeutics Institutional Ownership Celularity Institutional Ownership Adicet Bio Institutional Ownership Journey Medical Institutional Ownership Cidara Therapeutics Institutional Ownership Adlai Nortye Institutional Ownership Cellectis Institutional Ownership INmune Bio Institutional Ownership This page (NASDAQ:INKT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
